<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03272347</url>
  </required_header>
  <id_info>
    <org_study_id>8591-011</org_study_id>
    <secondary_id>2017-000437-32</secondary_id>
    <nct_id>NCT03272347</nct_id>
  </id_info>
  <brief_title>MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)</brief_title>
  <acronym>DRIVE2Simplify</acronym>
  <official_title>A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, antiretroviral activity, and
      pharmacokinetics of 3 doses of MK-8591 in combination with doravirine (DOR) and lamivudine
      (3TC) administered to antiretroviral treatment-naïve adult participants with human
      immunodeficiency virus type 1 (HIV-1) infection.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">September 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 9, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Masking in Part 1, including matching placebo. Masking only to dose in Part 2. No masking in Part 3.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-1 RNA at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants with HIV-1 RNA &lt;50 copies/mL at Week 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV-1 RNA at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with HIV-1 RNA &lt;50 copies/mL at Week 48</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to Week 126</time_frame>
    <description>Number of participants experiencing AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discontinuations</measure>
    <time_frame>Up to Week 120</time_frame>
    <description>Number of participants discontinuing study drug due to AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA up to Week 72</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants with HIV-1 RNA &lt;50 copies/mL up to 48 weeks after 3TC and placebo are discontinued from the regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T-cell count at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline in mature T-helper (CD4+ T)-cell count at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T-cell count at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in CD4+ T-cell count at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T-cell count at Week 96</measure>
    <time_frame>Baseline and Week 96</time_frame>
    <description>Change from baseline in CD4+ T-cell count at Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA up to Week 96</measure>
    <time_frame>Up to Week 96</time_frame>
    <description>Percentage of participants with HIV-1 RNA &lt;50 copies/mL up to 72 weeks after 3TC and placebo are discontinued from the regimen</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>MK-8591 0.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated once daily (QD) with 0.25 mg MK-8591, 100 mg DOR, 300 mg 3TC, and placebo to MK- 1439A for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to MK-1439A may be discontinued. Around Week 60, participants may be switched to a selected open label dose of MK-8591 and DOR 100 mg QD and continue treatment until Week 120.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8591 0.75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated QD with 0.75 mg MK-8591, 100 mg DOR, 300 mg 3TC, and placebo to MK- 1439A for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to MK-1439A may be discontinued. Around Week 60, participants may be switched to a selected open label dose of MK-8591 and DOR 100 mg QD and will continue treatment until Week 120.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8591 2.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated QD with 2.25 mg MK-8591, 100 mg DOR, 300 mg 3TC, and placebo to MK- 1439A for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to MK-1439A may be discontinued. Around Week 60, participants may be switched to a selected open label dose of MK-8591 and DOR 100 mg QD and will continue treatment until Week 120.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-1439A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated QD with placebo to MK-8591, placebo to DOR, placebo to 3TC, and MK-1439A consisting of 100 mg DOR + 300 mg 3TC + 300 mg tenofovir disoproxil fumarate (TDF) for a minimum of 24 weeks. Between week 24 through week 52 placebo treatments may be discontinued and participants will receive only MK-1439A QD open label up to Week 120.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8591</intervention_name>
    <description>MK-8591 at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected dose may be administered.</description>
    <arm_group_label>MK-8591 0.25 mg</arm_group_label>
    <arm_group_label>MK-8591 0.75 mg</arm_group_label>
    <arm_group_label>MK-8591 2.25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-8591</intervention_name>
    <description>Placebo to MK-8591 is orally administered QD in capsule form for up to 52 weeks</description>
    <arm_group_label>MK-1439A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine</intervention_name>
    <description>Doravirine 100 mg is orally administered QD in tablet form for up to 120 weeks</description>
    <arm_group_label>MK-8591 0.25 mg</arm_group_label>
    <arm_group_label>MK-8591 0.75 mg</arm_group_label>
    <arm_group_label>MK-8591 2.25 mg</arm_group_label>
    <other_name>MK-1439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Doravirine</intervention_name>
    <description>Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks</description>
    <arm_group_label>MK-1439A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks</description>
    <arm_group_label>MK-8591 0.25 mg</arm_group_label>
    <arm_group_label>MK-8591 0.75 mg</arm_group_label>
    <arm_group_label>MK-8591 2.25 mg</arm_group_label>
    <other_name>3TC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Lamivudine</intervention_name>
    <description>Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks</description>
    <arm_group_label>MK-1439A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-1439A</intervention_name>
    <description>MK-1439A consisting of 100 mg Doravirine + 300 mg Lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 120 weeks.</description>
    <arm_group_label>MK-1439A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-1439A</intervention_name>
    <description>Placebo to MK-1439A is orally administered QD in tablet form for up to 52 weeks</description>
    <arm_group_label>MK-8591 0.25 mg</arm_group_label>
    <arm_group_label>MK-8591 0.75 mg</arm_group_label>
    <arm_group_label>MK-8591 2.25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has HIV-1 infection

          -  Is naïve to anti-retroviral therapy (ART).

          -  Is clinically stable, with no signs or symptoms of acute infection, at the time of
             entry into the study

          -  Female is not pregnant, not breastfeeding, not a woman of childbearing potential
             (WOCBP); but if WOCBP agrees to follow the contraceptive guidance

          -  All participants, male and female, agree to use barrier methods of contraception when
             engaged in any sexual activity during treatment and for 6 weeks following treatment.

        Exclusion Criteria:

          -  Is a user of recreational or illicit drugs or has had a history of drug or alcohol
             abuse or dependence that may interfere with trial participation

          -  Has significant hypersensitivity or other contraindication to any of the components of
             the study drugs

          -  Has a history of malignancy ≤5 years prior

          -  Female expects to donate eggs at any time during the study

          -  Is breastfeeding or expecting to conceive

          -  A WOCBP who has a positive urine pregnancy test on Day 1 before the first dose of
             study treatment

          -  Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an
             agent that is active against HIV-1

          -  Has used systemic immunosuppressive therapy or immune modulators within 30 days prior
             to treatment in this study or is anticipated to need them during the course of the
             study

          -  Requires any of the following prohibited medications: Carbamazepine, Phenobarbital,
             Phenytoin, Rifabutin, Rifampin, Herbal remedies, St. John's Wort, Modafinil, Bosentan,
             Nafcillin, Pentostatin

          -  Is currently participating in or has participated in an interventional clinical trial
             with an investigational compound or device within 30 days of signing informed consent
             to participate in this current trial

          -  Has a documented or known virologic resistance to any approved HIV-1 reverse
             transcriptase inhibitor, protease inhibitor, integrase inhibitor

          -  Has active hepatitis C virus (HCV) coinfection defined as detectable HCV RNA or HBV
             co-infection defined as hepatitis B surface antigen [HBsAg]-positive

          -  Has a current (active) diagnosis of acute hepatitis due to any cause

          -  Has previously been randomized in a study and received MK-8591, DOR, MK-1439A, or 3TC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pueblo Family Physicians ( Site 0119)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University California / Davis ( Site 0101)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whitman Walker Clinic ( Site 0108)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center (OIC) ( Site 0105)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northstar Medical Center ( Site 0102)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City CARE Clinic ( Site 0106)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Hope Foundation, Inc. ( Site 0116)</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Infectious Diseases Consultants, PA ( Site 0103)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tarrant County Infectious Disease Associates ( Site 0112)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Crofoot Research Center, Inc. ( Site 0118)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Arauco Salud ( Site 0200)</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedica Research Group ( Site 0202)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Hernan Henriquez Aravena ( Site 0203)</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne ( Site 2302)</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Andre ( Site 2307)</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hotel Dieu ( Site 2308)</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice Hopital Archet 1 ( Site 2303)</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat - Claude Bernard ( Site 2309)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere ( Site 2305)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis ( Site 2306)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Tourcoing ( Site 2301)</name>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals NHS Trust ( Site 2105)</name>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital ( Site 2101)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital ( Site 2103)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free London NHS Foundation Trust ( Site 2102)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital ( Site 2104)</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2017</study_first_submitted>
  <study_first_submitted_qc>September 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

